35 results on '"Rapakko, Katrin"'
Search Results
2. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
3. Germline alterations in the 53BP1 gene in breast and ovarian cancer families
4. Clinical first-trimester routine screening for Down syndrome in singleton pregnancies in northern Finland
5. Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families
6. Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer
7. A recurrent mutation in PALB2 in Finnish cancer families
8. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability
9. Association of common ATM polymorphism with bilateral breast cancer
10. BRCA1 mislocalization leads to aberrant DNA damage response in heterozygous ABRAXAS1 mutation carrier cells
11. Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families
12. Abstract 339: Heterozygous germline mutation in ABRAXAS causes BRCA1 mislocalization and DNA damage response defects
13. Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility
14. Targeted Next-Generation Sequencing Identifies a Recurrent Mutation in MCPH1 Associating with Hereditary Breast Cancer Susceptibility
15. Favorable therapeutic responses in newly diagnosed CML-CP patients induced by Dasatinib are reflected at the CD34+CD38+Progenitor cell but not at the CD34+CD38-Stem cell level : Results from randomized NordCML006 study
16. Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+Progenitor Cell but Not At the CD34+CD38-Stem Cell Level: Results From Randomized NordCML006 Study in BLOOD, vol 118, issue 21, pp 356-356
17. The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study
18. Heterozygous mutations in PALB2 cause DNA replication and damage response defects
19. Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.
20. Genome-wide scanning for linkage in Finnish breast cancer families.
21. Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study
22. Screening for large genomic rearrangements in the FANCA gene reveals extensive deletion in a Finnish breast cancer family
23. The Proportion of Ph+ CD34+CD38neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study
24. Low or Undetectable Numbers of Philadelphia Chromosome Positive (Ph+) Leukemia Cells in the Primitive (CD34posCD38neg) Stem Cell Fraction in Chronic Myeloid Leukemia (CML) Patients during Tyrosine Kinase Inhibitor Therapy.
25. Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer
26. Mutation analysis of the ATRgene in breast and ovarian cancer families
27. Association of commonATM polymorphism with bilateral breast cancer
28. Erratum: Genome-wide scanning for linkage in Finnish breast cancer families
29. UBE3A gene mutations in finnish Angelman syndrome patients detected by conformation sensitive gel electrophoresis
30. Genome-wide scanning for linkage in Finnish breast cancer families
31. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland
32. Mutation analysis of the ATR gene in breast and ovarian cancer families
33. <TOGGLE>UBE3A</TOGGLE> gene mutations in finnish Angelman syndrome patients detected by conformation sensitive gel electrophoresis<FNR HREF="fn1"></FNR><FN ID="fn1">Katrin Rapakko and Hannaleena Kokkonen contributed equally to the study.</FN>
34. The Proportion of Ph+ CD34+CD38negLeukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study
35. Genome-wide scanning for linkage in Finnish breast cancer families.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.